Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug vedotin + tislelizumab + low-dose lenvatinib in advanced esophageal squamous cell carcinoma (post–first-line failure)
ChiCTR2600129001Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin, tislelizumab and lenvatinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
becotatug vedotintislelizumablenvatinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600129001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129001.